A peer-level look at what endocrinology and diabetes clinicians see after a GLP-1 or dual GIP/GLP-1 prescription is written: where cost, gastrointestinal symptoms, expectations, titration, and support determine whether treatment can continue.
Audience: Endocrinologists
Countries: 6
Completion Rate: 90%
SGID: 8933360
-Hero findings
– Quick Read — Key Findings
Current guidance increasingly treats obesity pharmacotherapy as chronic care. That makes the weeks and months after treatment initiation just as important as choosing the medicine itself.
In the MDForLives survey, clinicians were not asked only whether GLP-1 and dual GIP/GLP-1 therapy works. They were asked what happens when patients encounter cost, gastrointestinal symptoms, unrealistic expectations, dose escalation, treatment plateaus, and the need for longer-term support. The answer is a persistence story built from several points of friction.
External guidance provides useful context. The American Diabetes Association’s 2026 Standards emphasize individualized titration to balance efficacy and tolerability and support continuing chronic obesity pharmacotherapy when it remains appropriate. WHO’s 2025 guideline likewise frames GLP-1 therapy within long-term, comprehensive obesity care while highlighting affordability, equity, and health-system readiness as implementation challenges.
When asked for the single most frequent reason patients stop GLP-1 therapy prematurely, 63.0% point to high out-of-pocket cost or lack of insurance reimbursement.
In plain terms, money is the number one reason people stop, and it sits well ahead of side effects or unmet expectations. Doctors pointed to cost about two and a half times more often than they pointed to stomach problems. When we asked what would help people stay on treatment in the years ahead, most named the same thing again: lower prices and better insurance coverage, ahead of any newer version of the medicine. So for many patients, staying on treatment is as much about what they can afford as it is about how well the medicine works. Looking at the exact figures, 63.0% named high out-of-pocket cost or no insurance reimbursement as the single most common reason people stop, compared with 25.9% who pointed to ongoing stomach side effects and 11.1% to unrealistic expectations or an early plateau.
The largest group, 40.7%, estimates that 10–25% of patients prescribed GLP-1/GIP therapy primarily for weight management discontinue within the first 12 months.
There is no single “quit rate” that fits everyone. Most doctors estimate that somewhere between 10 and 25 out of every 100 patients stop within the first year, and a similar number think it is even higher. Only a few see very low numbers. The takeaway is that some people stopping early is normal and expected, not a surprise. That is exactly why the first steps matter so much: setting clear expectations, checking what the medicine will actually cost, and staying on top of side effects, all before they become a reason to give up. In the exact figures, 40.7% put the first-year stop rate at 10–25%, 22.2% at 26–40%, 14.8% at 41–55%, and 7.4% above 55%, while 11.1% said under 10% and 3.7% did not track it.
51.9% say gastrointestinal side effects only occasionally account for treatment discontinuations before the target maintenance dose is reached.
Side effects like nausea are common, but they are usually not what ends treatment. Only about 1 in 10 doctors said side effects are a frequent reason people stop. When symptoms do get hard to manage, most doctors do not give up on the medicine. About half lower the dose and pause for a while, some move to a different version, and others bring in diet or counseling support. Very few stop the medicine altogether. In short, the usual response is to adjust and keep going, not to quit. In the exact figures, 51.9% said side effects only occasionally cause stopping and 11.1% said rarely, while 25.9% said frequently and 11.1% very frequently. When a change is needed, 51.9% lower the dose and pause, 22.2% switch versions, 18.5% add diet or counseling support, and just 7.4% stop the medicine.
Three different misconceptions each attract 29.6% of responses: expecting dramatic early loss, believing medication removes the need for diet and exercise, and expecting weight loss to remain permanent after stopping.
40.7% choose slower, personalized titration and another 40.7% choose comprehensive pre-treatment counseling as the most effective strategy for improving one-year persistence.
Two approaches came out on top, and both happen early, before any problems start. One is going slow and steady with the dose; the other is a good conversation before treatment begins, so people know what to expect. The more reactive options, like handling side effects only once they appear or leaning on app reminders, ranked much lower, with reminders coming in last. The lesson is simple: the best time to help someone stay on treatment is right at the start, by matching the pace of the medicine to the person and preparing them for what lies ahead. In the exact figures, personalized titration and pre-treatment counseling tied at 40.7% each, well ahead of proactive GI side-effect management at 14.8% and digital tools or reminders at just 3.7%.
Across the findings, the biggest threat to persistence is not a single adverse effect or a single unrealistic expectation. It is the accumulation of friction. Cost can make the medicine unreachable, GI symptoms can make titration difficult, expectations can make normal progress feel like failure, and limited support can leave the patient making continuation decisions between visits.
For endocrinologists and diabetes specialists, the practical opportunity is to move persistence work earlier. Check affordability before the plan hardens. Explain how dose escalation can be adjusted. Prepare patients for a chronic treatment horizon, not an instant result. Decide who needs multidisciplinary support and who can be managed with focused follow-up. When these pieces are aligned, continuation becomes part of clinical design rather than a problem discovered after the patient disappears from therapy.
Verify coverage, out-of-pocket burden, and what the fallback is if reimbursement changes.
Make dose escalation adaptable enough that early GI symptoms do not force an avoidable stop.
Set realistic expectations for pace, lifestyle participation, side effects, and what may happen after discontinuation.
You have read the summary
Direct answers to common questions around this topic.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
